Edwards Lifesciences Corp EW

$88.05 +0.83 (0.95%)

Valuation

Market cap
49,864,280,000
Revenue TTM
$6,067,600,000
Net income TTM
$1,073,500,000
PE ratio
31.35
Forward PE
29.35
Profit margin
17.69%
Debt to equity
0.06

Trading

Volume
889,170
Avg volume
3,330,162
Day's range
$87.16 – $88.34
Shares out
575,800,000
Stochastic %K
80%
Beta
0.87
Analysts
Strong Sell
Price target
$101.89

Price

Company profile

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricu...

Show more

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Industry
Medical Devices
Sector
Healthcare
Phone
949 250 2500
Website
https://www.edwards.com
Address
One Edwards Way, Irvine, United States

Latest news

Stocktwits

XxGodFatherxX Oct 19, 8:35 PM
$EW good long term short as their TAVR program gets dismantled by innovation from competitors
0 replies
thatsolardude365 Oct 18, 12:00 PM
$EW: 45 days left in the $39M Edwards settlement. Your broker will not file for you, and Kroll does not have your trades. Gather Feb to July 2024 statements now. About $0.66 a share before fees, claim by Dec 2. Open Class Actions.
0 replies
thatsolardude365 Oct 16, 7:36 AM
$EW: shares held in an Edwards employee plan do not count in the $39M settlement. Only stock bought outside the plan qualifies, options do not count either, and payments under $10 are not issued. Claim by Dec 2. Open Class Actions.
0 replies
11thestate Oct 15, 1:26 PM
Shareholders who bought $EW between 2024 and 2024 have until December 2, 2026 to file a claim in the $39M settlement. The settlement claims that Edwards Lifesciences misled investors about the growth prospects of its TAVR platform. After the company lowered its revenue forecast for 2024, $EW fell more than 31%. Eligible investors can submit a claim before the deadline: https://11th.com/cases/edwards-lifesciences-investor-suit
0 replies
thatsolardude365 Oct 14, 6:49 PM
$EW: Dec 2 does triple duty in the Edwards settlement. Claims, opt-outs and objections are all due that day. Final approval is Dec 16. Held shares through the July 24, 2024 close? About $0.66 a share before fees. Open Class Actions.
0 replies
XxGodFatherxX Oct 13, 5:21 PM
$EW stale company. Lacks innovation
0 replies
thatsolardude365 Oct 13, 6:15 AM
$EW: bought Edwards stock Feb to July 2024 and sold before July 24? That claim pays $0. Only shares still held at the July 24 close count in the $39M settlement, about $0.49 a share after max fees. Claim by Dec 2. Open Class Actions.
0 replies
thatsolardude365 Oct 11, 7:43 AM
$EW reminder: 7 weeks left on the $39M Edwards Lifesciences settlement. Held EW shares during the alleged TAVR growth misstatement period? Roughly $0.66 a share estimated, brokerage records needed. Claims close Dec 2. Open Class Actions.
0 replies